Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Gene Therapy

• Publication date

  2000-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.cgt.7700202PMID 10917202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent and selective gene inhibition using antisense oligodeoxynucleotides

  2004cited by this paper
• Activation of Rb and decline in androgen receptor protein precede retinoic acid–induced apoptosis in androgen‐dependent LNCaP cells and their androgen‐independent derivative

  1999cited by this paper
• Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

  1999cited by this paper
• The Androgen Receptor Gene Mutations Database

  1998cited by this paper
• Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

  1997cited by this paper
• Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?

  1997cited by this paper
• Androgen Receptor Gene Mutations in Prostate Cancer

  1997cited by this paper
• [Androgen receptor gene mutations in prostate cancer].

  1997cited by this paper
• Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.

  1997cited by this paper
• Androgen Receptor Structure and Prostate Cancer

  1996cited by this paper
• Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway*

  1996cited by this paper
• The androgen receptor gene mutations database

  1996cited by this paper
• The development of Casodex (bicalutamide): preclinical studies.

  1996cited by this paper
• Androgen receptor status of lymph node metastases from prostate cancer

  1996cited by this paper
• Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.

  1996cited by this paper
• Regulation of prostatic growth and function by peptide growth factors

  1996cited by this paper
• The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP.

  1996cited by this paper
• A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

  1996cited by this paper
• Endocrine control of prostate cancer.

  1995cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Distant metastases from prostatic carcinoma express androgen receptor protein.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995cited by this paper
• Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.

  1995cited by this paper
• Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

  1995cited by this paper
• Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

  1995cited by this paper
• Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

  1994cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

  1994cited by this paper
• Gene inhibition using antisense oligodeoxynucleotides

  1994cited by this paper
• Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene.

  1993cited by this paper
• Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy.

  1993cited by this paper
• Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

  1993cited by this paper
• Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups.

  1992cited by this paper
• Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation.

  1992cited by this paper
• Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer.

  1991cited by this paper
• Androgen receptors in endocrine‐therapy‐resistant human prostate cancer

  1991cited by this paper
• A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

  1990cited by this paper
• Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

  1990cited by this paper
• The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines.

  1990cited by this paper
• Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines.

  1990cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

  1989cited by this paper
• Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.

  1988cited by this paper
• Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

  1988cited by this paper
• Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP

  1988cited by this paper
• Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids

  1988cited by this paper
• Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

  1987cited by this paper
• Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.

  1981cited by this paper
• The LNCaP cell line--a new model for studies on human prostatic carcinoma.

  1980cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper
• Isolation of a human prostate carcinoma cell line (DU 145)

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976influential reference

• Revisiting the roles of cAMP signalling in the progression of prostate cancer

  2023cites this paper
• Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective

  2022cites this paper
• Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung

  2020cites this paper
• ADAMTS-15 Has a Tumor Suppressor Role in Prostate Cancer

  2020cites this paper
• Fc‐Binding Antibody‐Recruiting Molecules Targeting Prostate‐Specific Membrane Antigen: Defucosylation of Antibody for Efficacy Improvement **

  2020cites this paper
• ARe we there yet? Understanding androgen receptor signaling in breast cancer

  2020cites this paper
• Resistance to anti-hormonal therapy in prostate cancer

  2019cites this paper
• Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins

  2018cites this paper
• Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

  2017cites this paper
• A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

  2017cites this paper
• Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.

  2017cites this paper
• Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer

  2016cites this paper
• TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.

  2016cites this paper
• Study on the Effect of Herba Sarcandrae on Proliferation and Apoptosis of Prostate Cancer DU -145 Cell

  2016cites this paper
• MicroRNA-185 downregulates androgen receptor expression in the LNCaP prostate carcinoma cell line.

  2015cites this paper
• Promoter hypermethylation as a biomarker in prostate adenocarcinoma.

  2015cites this paper
• Combinatorial targeting of the androgen receptor for prostate cancer therapy

  2015cites this paper
• Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells

  2015cites this paper
• Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

  2014cites this paper
• Targeting the androgen receptor in prostate cancer

  2014cites this paper
• Androgen receptor signaling in prostate cancer

  2014cites this paper
• Los efectos de resveratrol y otros polifenoles del vino sobre la proliferación, apoptosis y expresión de receptor androgénico en células LNCaP

  2014cites this paper
• Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells.

  2014cites this paper
• Inhibition of the IL-6/STAT3 signaling pathway for therapeutic intervention in prostate carcinogenesis and cancer cell differentiation

  2013cites this paper
• Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G1 to S Phase

  2013cites this paper
• Lipid nanoparticles encapsulating siRNAs against the androgen receptor to treat advanced prostate cancer

  2013influential citation
• Regulation of androgen receptor expression by Z‐isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer

  2013cites this paper
• Effect of Antisense Mediated BCL-2 Suppression on the Expression of the Androgen Receptor and Coactivating p300 and CREB Binding Proteins

  2013cites this paper
• Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model

  2013cites this paper
• Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression

  2013cites this paper
• Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3

  2013cites this paper
• Integration of Regulatory Networks by NKX3-1 Promotes Androgen-Dependent Prostate Cancer Survival

  2012cites this paper
• Differential Functions of Stromal and Epithelial Androgen Receptor in Prostate Cancer Before and After Castration Resistant Stage

  2012cites this paper
• DNA methylation in promoter region as biomarkers in prostate cancer.

  2012cites this paper
• Reconstruction And Analysis Of The Molecular Programs Involved In Deciding Mammalian Cell Fate

  2012cites this paper
• Tumor Compensation Associated With Gene Therapy

  2012cites this paper
• The curcumin analog ca27 down‐regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells

  2012cites this paper
• Multiple Pathways Compensate for Antisense Suppression of Bcl-2 in LNCaP Cells Contributing to Tumor Resistance

  2012cites this paper
• miR 488* inhibits androgen receptor expression in prostate carcinoma cells

  2011cites this paper
• In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2

  2011cites this paper
• In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides

  2011cites this paper
• Advanced Models for Target Validation & Drug Discovery in Prostate Cancer

  2011cites this paper
• CTP: Phosphocholine Cytidyltransferase Alpha (CCTα) siRNA Induce Cell Death of Lung Cancer Cells

  2011cites this paper
• Étude de Necdin par un modèle de carcinogénèse lié à l’antigène grand T du Virus du polyome

  2011cites this paper
• Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells*

  2011cites this paper
• HAPLOTYPE-BASED PROSTATE CANCER ASSOCIATION STUDY IN AFRO- CARIBBEANS OF TOBAGO

  2010cites this paper
• Promoter hypermethylation in prostate cancer.

  2010cites this paper
• Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

  2010cites this paper
• Role of androgen receptor in prostate cancer cell cycle regulation: interaction with cell cycle regulatory proteins and enzymes of DNA synthesis.

  2010cites this paper
• Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems

  2010cites this paper
• Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Purα‐mediated decrease in androgen receptor levels

  2010cites this paper
• Haplotype-based prostate cancer association study in Afro-Caribbeans of Tobago

  2010cites this paper
• A Simple Technique for the Prediction of Interacting Proteins Reveals a Direct Brn-3a-Androgen Receptor Interaction*

  2010cites this paper
• Mining Natural Product-Derived Molecules Against Cancer Targets: The Case of the Androgen Receptor in Prostate Cancer

  2010cites this paper
• Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants

  2010cites this paper
• A Study Of Cell Growth, Division And Programmed Differentiation By Simulation And Experiments.

  2010cites this paper
• Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A

  2010cites this paper
• Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.

  2009cites this paper
• The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

  2009cites this paper
• CHANGES OF ErbB-RELATED SURVIVAL SIGNALINGS BETWEEN ANDROGEN-DEPENDENT AND -INDEPENDENT TRANSITION OF PROSTATE CANCER CELLS

  2009cites this paper
• Ligand-independent androgen receptor activity

  2009cites this paper
• Mechanistic investigation of an anticancer agent that damages DNA and interacts with the androgen receptor

  2009cites this paper
• Role of IL-6 in Regulating the Androgen Receptor

  2009cites this paper
• Molecular Biology of Novel Targets Identified Through Study of Castration-Recurrent Prostate Cancer

  2009cites this paper
• Steroid receptors as molecular targets for cancer diagnosis and therapy.

  2009cites this paper
• Relationships among antioxidants, phenolics, and specific gravity in potato cultivars, and evaluation of wild potato species for antioxidants, glycoalkaloids, and anti-cancer activity on human prostate and colon cancer cells in vitro.

  2009cites this paper
• Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo

  2008cites this paper
• 5α‐androstane‐3α,17β‐diol supports human prostate cancer cell survival and proliferation through androgen receptor‐independent signaling pathways: Implication of androgen‐independent prostate cancer progression

  2008cites this paper
• Signal Transduction by the Ras–MAP Kinase Pathway in Prostate Cancer Progression

  2008cites this paper
• New directions in endocrine therapy: renewed interest in the androgen receptor

  2008cites this paper
• Characterisation of a dominant negative androgen receptor in prostate cancer cells.

  2008cites this paper
• Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.

  2008cites this paper
• Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

  2008cites this paper
• Étude de l'impact des récepteurs non stéroïdiens sur l'activité androgénique dans les cellules cancéreuses de la prostate

  2008cites this paper
• Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.

  2008cites this paper
• GKLF as a Novel Target in Selenium Chemoprevention of Prostate Cancer

  2008cites this paper
• AUTHOR COPY ONLY Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells

  2008cites this paper
• Oligomeric proanthocyanidin complexes (OPC) exert anti‐proliferative and pro‐apoptotic effects on prostate cancer cells

  2008cites this paper
• Interplay of Nuclear Factor-κB and B-myb in the Negative Regulation of Androgen Receptor Expression by Tumor Necrosis Factor α

  2008cites this paper
• Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.

  2008cites this paper
• Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts

  2008cites this paper
• Somatic Genetic Changes in Prostate Cancer

  2008cites this paper
• GENE EXPRESSIONS IN HUMAN PROSTATE LNCAP XENOGRAFTS: EFFECTS OF ALPHA- TOCOPHERYL SUCCINATE ( -TOS) AND DIETARY SOYBEAN OIL

  2007cites this paper
• Non‐steroidal antiandrogens act as AF‐1 agonists under conditions of high androgen‐receptor expression

  2007cites this paper
• Androgen Receptor Function in Prostate Cancer Progression

  2007cites this paper
• Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells

  2007cites this paper
• Alpha-tocopheryl succinate (α-TOS) modulates human prostate LNCaP xenograft growth and gene expression in BALB/c nude mice fed two levels of dietary soybean oil

  2007cites this paper
• Androgen receptor structural and functional elements: role and regulation in prostate cancer.

  2007cites this paper
• Transcription factors: molecular targets for prostate cancer intervention by phytochemicals.

  2007cites this paper
• The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.

  2007cites this paper
• Increased resistance to trail‐induced apoptosis in prostate cancer cells selected in the presence of bicalutamide

  2007cites this paper
• Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells

  2007cites this paper
• Award Number: W81XWH-04-1-0214 TITLE: Inhibition of Androgen-Independent Growth of Prostate Cancer by siRNA- Mediated Androgen Receptor Gene Silencing

  2006influential citation
• Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.

  2006cites this paper
• Androgen axis in prostate cancer

  2006cites this paper
• Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells*

  2006cites this paper
• The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide

  2006cites this paper
• Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action

  2006cites this paper
• Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells

  2006cites this paper
• TITLE : Mechanism of Selenium Chemoprevention and Therapy in Prostate Cancer PRINCIPAL INVESTIGATOR :

  2006cites this paper